Clinical trial
Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat…
NCT00456508 · Shire, Industry · Completed
Key facts
| NCT number | NCT00456508 |
|---|---|
| Title | Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE) |
| Official title | Open-label Patient Continuation of DX-88 (Ecallantide) for Acute Hereditary Angioedema Attacks |
| Lead sponsor | Shire, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hereditary Angioedema (HAE) |
| Intervention type | Drug |
| Interventions | ecallantide |
| Enrollment | 147 |
| Start date | Apr 1, 2007 |
| Primary completion | Jun 1, 2010 |
| Completion | Sep 1, 2010 |
| First posted | Apr 5, 2007 |
| Last update posted | Jun 8, 2021 |
| Countries | Canada, Jordan, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: